Biosimilar Therapeutic Peptides Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA

"The new report published by The Business Research Company, titled ""Biosimilar Therapeutic Peptides Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the biosimilar therapeutic peptides market size has grown exponentially in recent years. It will grow from $2.06 billion in 2023 to $2.68 billion in 2024 at a compound annual growth rate (CAGR) of 30.3%. The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $4.87 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp

Increasing Aging Population Drives Demand For Biosimilar Therapeutic Peptides In Chronic Disease Management
The increasing ageing population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides' market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world's population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the growth of biosimilar market.

Fujitsu Launches Biodrug Design Accelerator Platform To Revolutionize Peptide Drug Discovery
Major companies in the biosimilar therapeutic peptide market are developing a research platform for optimizing peptide synthesis, enhancing production efficiency, and ensuring consistent quality, from discovery to commercialization. Biodrug Design Accelerator, a platform to manage research processes for peptide drug discovery, which many regard as a promising frontier in the field of new drug development. For instance, in May 2023, Fujitsu Limited. A US-based toy manufacturing and entertainment company, launched the Biodrug Design Accelerator platform to accelerate peptide drug discovery research. Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles design, make, test, analyze (DMTA), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing.

The biosimilar therapeutic peptides market covered in this report is segmented -

1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=3423&type=discount

Major companies operating in the biosimilar therapeutic peptides market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., Hyperion Therapeutics Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.

Contents of the report:
1. Executive Summary
2. Biosimilar Therapeutic Peptides Market Report Structure
3. Biosimilar Therapeutic Peptides Market Trends And Strategies
4. Biosimilar Therapeutic Peptides Market - Macro Economic Scenario
5. Biosimilar Therapeutic Peptides Market Size And Growth
…..
27. Biosimilar Therapeutic Peptides Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.